Loading clinical trials...
Loading clinical trials...
This is a multi-center, phase I, open clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of TWP-102 injection in patients with advance...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Shandong TheraWisdom Biopharma Co., Ltd.
NCT04752826 · Advanced Malignancies, Ovarian Cancer, and more
NCT06458712 · Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
NCT06717880 · Advanced Malignancies
NCT06468098 · Advanced Malignancies
NCT05891171 · Advanced Cancer, Advanced Malignancies, and more
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions